Successful treatment with daclizumab of refractory anaplastic lymphoma.

Full Abstract

Anaplastic large cell lymphoma (ALCL) is a relatively rare and highly malignant form of non-Hodgkin lymphoma (NHL) which accounts for 10-15% of these childhood lymphomas. Current treatment protocols for ALCL in children consist of a short course of high intensity polychemotherapy. Here we describe an 8-year-old female with relapsed ALCL who achieved good response with anti-CD25 monoclonal antibody daclizumab. Daclizumab appears to offer a safe treatment option, but further research needs to be conducted in order to define its role in children with ALCL who do not respond to intensive chemotherapy.

Author information

Author/s: Costa, Vítor (V); Oliva, Teresa (T); Norton, Lucília (L);

Affiliation: Departamento de Pediatria, Instituto Português de Oncologia Francisco Gentil, Porto, Portugal. vitormendescosta(-atsign-)hotmail.com

Journal and publication information

Publication Type: Case Reports; Journal Article

Journal: Pediatric blood & cancer (Pediatr Blood Cancer), published in United States. (Language: eng)

Reference: 2009-Dec; vol 53 (issue 6) : pp 1130-1

Dates: Created 2009/09/16; Completed 2009/10/13;

PMID: 19598219, status: MEDLINE (last retrieval date: 10/13/2009, IMS Date: )

Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.

External Links for this article
(including full text providers, if available):

Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.

This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.